- Global Pharma News & Resources

Gilead Sciences Announces Launch of Asia Pacific Rainbow Grant 2019

HONG KONG, July 3, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced the launch of the 2019 Gilead Asia Pacific Rainbow Grant program, a grant initiative that supports community-led programs for people living with HIV in the Asia Pacific region. Non-governmental or advocacy organizations are invited to submit their applications for 2019 funding online at starting today. The submission deadline ends on 30 September 2019, 11:59pm GMT+8.

This year's grant program seeks to improve the quality of life of people living with HIV by focusing on three priority areas: 1) access and quality of life; 2) multidisciplinary care; and 3) diversity and inclusion.

In 2016, UNAIDS established the 90-90-90 targets, which aim to diagnose 90 percent of all HIV-positive persons, provide treatment to 90 percent of those diagnosed and achieve viral suppression for 90 percent of those treated.[1] However, as HIV care evolves, there is an increasing need to look at HIV outcomes beyond viral suppression. The "Fourth 90," an additional target to the UNAIDS 90-90-90 goals, adds a focus on the experience of people living with the disease, setting a target to ensure their care extends beyond viral suppression to health-related quality of life.[2]

"At Gilead, we believe that strong community partnerships can have a significant impact in improving the care and support for people living with serious diseases," said Amy Flood, Senior Vice President, Public Affairs, Gilead Sciences. "Gilead's Asia Pacific Rainbow Grant program is one way that we work with community groups and support projects that place people at the center of care. We look forward to supporting organizations in the region to enable people living with HIV to reach their fullest potential each day and live a fulfilling life."

Gilead has expanded the grant program to 18 countries or territories in the region - nearly doubling the geographic scope from last year's program. More than US$1 million was awarded to 28 organizations across 10 countries or territories last year.

To find out more about the Gilead Asia Pacific Rainbow Grant program, please visit:

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with global headquarters in Foster City, California.

For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Today, it's estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company's generic manufacturing partners.

For more information on Gilead Sciences, please visit the company's website at, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

[1] 90–90–90 - An ambitious treatment target to help end the AIDS epidemic, last accessed 21 June 2019.

[2] Beyond viral suppression of HIV – the new quality of life frontier (2016), last accessed 21 June 2019.

Media Contact:

Agnes Lau
+852 9857 1399

Logo -

SOURCE Gilead Sciences, Inc.

Editor Details

Last Updated: 03-Jul-2019